Biogen Q2 Preview: Can It Change The Narrative After Q1 Strength Was Overshadowed?
Executive Summary
Despite 11% sales growth during the first quarter, Biogen faces pessimism about continuing to pursue the amyloid hypothesis in Alzheimer’s and competitive threats to Spinraza and Tecfidera. ALS and biosimilars may offer upside.
You may also be interested in...
Biogen Growth Continues, But Analysts Worry About Near-Term R&D Prospects
The biotech’s MS franchise led by Tecfidera grew strongly, while SMA therapy Spinraza dipped slightly, but Biogen maintains optimistic outlook amidst growing competition.
Biogen Claims Lead Among Adalimumab Biosimilars In Europe
With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.
Biogen Stays Steady As Alzheimer’s Programs Falter
Still reeling from aducanumab’s failure in Phase III Alzheimer’s trial, Biogen management played up the company’s progress toward diversification and the promise of its pipeline.